Evidence map›Paper›PMID 42871608›Full record

ArticleAME case reports2026

Fatal multiple organ dysfunction syndrome induced by colchicine poisoning in a patient with underlying alcoholic liver disease: a case report.

Changqian Xiao, Youna Yu, Sufen He, Qihong Sun

Abstract readCase Reports
In one paragraph

Article in AME case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Changqian XiaoDepartment of Pharmacy, Zhejiang Hospital, Hangzhou, China.
Youna YuDepartment of Pharmacy, Shengsi People's Hospital, Zhoushan, China.
Sufen HeDepartment of Pharmacy, Shengsi People's Hospital, Zhoushan, China.
Qihong SunDepartment of Pharmacy, Shengsi People's Hospital, Zhoushan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Colchicine is a drug used primarily to treat and prevent gout. Yet its narrow therapeutic index makes the lethal dose highly variable, influenced by patient-specific factors such as hepatic function and concomitant medications. In vulnerable patients, even doses substantially below the traditionally cited lethal threshold can result in fatal outcomes. Case Description: We report a case of a 58-year-old male with a history of gout, alcoholic liver disease, and hyperlipidemia who presented with vomiting, diarrhea, and abdominal pain that lasted three days after ingesting 15 mg of colchicine (0.22 mg/kg) for gout pain relief. Upon admission, laboratory findings revealed acute kidney injury, severe metabolic acidosis, leukopenia, and thrombocytopenia. Despite aggressive supportive care in the intensive care unit (ICU), including broad-spectrum antibiotics, fluid resuscitation, steroids and recombinant human thrombopoietin (rhTPO), the patient developed progressive multiple organ dysfunction syndrome (MODS), disseminated intravascular coagulation (DIC), and spontaneous intracranial hemorrhage. On the eighth day of admission, the family opted to discontinue further organ support, and the patient died shortly thereafter. Conclusions: This case shows that in patients with hepatic impairment, severe colchicine toxicity and fatal outcomes may occur even at doses below the traditionally cited threshold. The case also demonstrates that it is critical for physicians to be alert to the serious adverse effects of inadvertent colchicine overdose when prescribing the drug.

Indexed as

case reportColchicinehepatic impairmentmultiple organ failurepoisoning

Identifiers

PMID42871608
PMCPMC13659155

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.